Japan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year ago, as the company shakes off the huge debts it incurred to get the deal done.
Newron’s share price has collapsed after the biotech axed development of its drug sarizotan for the rare genetic brain disorder Rett Syndrome following the failure of a key trial.
The FDA has approved Ongentys, an oral Parkinson’s Disease drug from US biotech Neurocrine Biosciences, which can be added to prolong the effects of standard therapy and help prevent “off”
Voice technology like Amazon’s Alexa is taking some big steps forward in healthcare and in the pharmaceutical world one of the companies working in this area is Eisai.
Novartis is off the hook following the FDA’s review of data manipulation in the filing of its hugely expensive spinal muscular atrophy gene therapy Zolgensma.
Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.